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OBJECTIVES: Discrete event simulation (DES) is a tool that allows for the 
organizational domain to be quantified within health technology assessment 
(HTA). This research demonstrates how DES can be used to model improved 
access to care for children with medically refractory epilepsy (MRE). METHODS: 
To develop the DES model from an organizational perspective, a collaborative 
effort is required between the clinical (SickKids) and HTA teams (PATH). We 
completed the analysis in several phases: mapping patient flow, collecting 
resource data, programming the simulation software (ARENA), and estimating 
model inputs. We validated the model for clinical and organizational content 
and goodness-of-fit with the system. Model outputs were flow and wait time (e.g. 
time to surgery). We conducted an analysis of resource capacities on outputs to 
increase access and reduce wait times (30 days to epilepsy monitoring unit 
(EMU), 1.5 years surgery with invasive monitoring and 1 year for surgery 
without). RESULTS: Several iterations were needed to validate patient flow and 
develop confidence in model predictions. Clinical care was described by 4 
modules: EMU (the entry point for diagnostic evaluation), multimodal diagnostic 
assessment, multidisciplinary seizure conference (SC), and surgery. Based on 
analysis of different resource capacities the following increases in resources 
were found to meet the institution’s goals: 2 EMU beds (30 days), 2 invasive 
monitoring surgeries (1.4 years) and 6 non-invasive monitoring surgeries (1 year) 
and limiting the number of repeat SCs to 2. CONCLUSIONS: DES can be used to 
analyze the organizational structure in HTA. Rate limiting factors and efficient 
resource configuration is possible to reach the goal of improving access by 
decreasing wait times. DES can be scaled up from the institution to inform policy 
for the health system overall. By incorporating patient and economic outcomes, 
DES can be used as a platform to bridge the domains of HTA.  
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OBJECTIVES: To calculate and compare the incremental cost-utility ratios for 
standard antiepileptic drug (AED) therapy with and without adjunctive 
lacosamide in patients with uncontrolled partial-onset seizures in Turkey. 
METHODS: A model simulated the treatment pathway of a hypothetical cohort 
of 1000 patients over two years from the third-party payer perspective in Turkey 
in 2012. A decision tree was split into four phases of six months during which 
patients could become seizure free, experience a response to treatment 
(responder defined as ≥50% reduction in seizures), or withdraw due to non-
response. The standard therapy arm included five adjunctive therapies: 
carbamazepine, lamotrigine, levetiracetam, topiramate, and valproate. The 
likelihood of being in a particular health state was estimated from clinical trial 
data. The cost of general practitioner visits, specialist visits, hospitalizations and 
emergency department visits were included. Costs and utility values attached to 
various health states were taken from the published literature. RESULTS: 
Compared with the standard therapy arm, lacosamide adjunctive therapy was 
associated with 6,730 seizures avoided and a gain of 38 quality adjusted life-
years (QALYs). Treatment with lacosamide was associated with an additional 
cost of Turkish Lira (TRY) 205 per seizure avoided and TRY 36,392 per QALY 
gained versus standard therapy without LCM over two years. Results calculated 
for 6-, 12- and 18-month follow-up showed respective incremental cost-utility 
ratios of TRY 38,146, TRY 37,629 and TRY 37,556 and cost per seizure avoided of 
TRY 504, TRY 246 and TRY 219. Sensitivity analysis indicates the base case 
findings are robust, however the model was most sensitive to changes in the 
utility weights. CONCLUSIONS: Lacosamide may be a cost-effective adjunctive 
treatment for patients with uncontrolled partial-onset epilepsy in Turkey. UCB-
funded  
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OBJECTIVES: Several published studies have reported the clinical and economic 
impact of adherence to disease-modifying therapies (DMTs) for multiple sclerosis 
(MS), although none have examined the impact of adherence exclusively in 
patients continuously enrolled for five years. The objectives of this study were to 
understand some of the clinical and economic outcomes associated with long-
term adherence/non-adherence to DMTs in MS patients. METHODS: Patients 
who had a medical or pharmacy claim for a DMT between January 1, 2005 to 
December 31, 2005 and who were continuously enrolled until December 31, 2011 
were included in this retrospective cohort study. A total of 664 patients met 
eligibility criteria, and were defined as adherent if they had a medication 
possession ratio (MPR) of greater than 80% in all five years. Propensity Score Bin-
Bootstrapping method was used to control for the variation between the 
adherent and non-adherent groups. Variables used to calculate propensity scores 
were age, gender, comorbidities and severity of disease. RESULTS: Compared 
with the non-adherent group, the adherent group had significantly fewer 
inpatient relapses per year (0.339 vs. 0.215, p<0.01) and had lower annual 
unadjusted medical costs. The non-adherent group had significantly higher 
(p<0.05) adjusted annual medical costs than their matched adherent 
counterparts in all 5 years of the study, except for year 1. From year 1 to year 5, 
adjusted medical costs increased 235% in the non-adherent group compared to 
93% in the adherent group. CONCLUSIONS: MS patients with consistently high 
medication adherence to DMTs over a 5 year period had lower rates of inpatient 
relapse and lower total medical costs than their non-adherent counterparts. 
Given the high cost of DMTs to both payers and patients, it is imperative to 
support and encourage high adherence when using these agents in order to get 
the most value out of the investment in DMTs.  
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OBJECTIVES: Lacosamide is an antiepileptic drug (AED) that enhances sodium 
channel slow inactivation and is approved for adjunctive treatment of partial-
onset seizures in adults. There have been few studies examining patient 
characteristics in patients receiving sodium channel blocking (SCB) versus non-
sodium channel blocking (nSCB) AEDs in addition to lacosamide. The objective of 
this study was to compare patient characteristics and health care utilization in 
nSCB and SCB patients prior to adding lacosamide in a real-world setting. 
METHODS: This was a retrospective database analysis using eligibility, medical 
and pharmacy claims data from a large US health care organization. For 
inclusion, patients had evidence of epilepsy, were continuously enrolled for 6 
months prior to (pre-index) and after (post-index) the 1stpharmacy claim for 
lacosamide (index date), and were receiving at least one other AED (SCB or nSCB) 
for 60 days prior to the index date. If patients were taking ≥1 SCB, they were 
assigned to the SCB group. RESULTS: A total of 720 patients (382 SCB, 338 nSCB) 
met study criteria. Mean age was 35.9 years; 55.7% were female. A total of 62.6% 
of SCB and 30.2% of nSCB patients (p<0.001) were receiving ≥2 AEDs prior to 
adding lacosamide. nSCB patients had higher mean pre-index Quan-Charlson 
Comorbidity (CCI) scores [0.94(SD 1.48) versus 0.49(1.07); p<0.001] and epilepsy-
attributable events [0.56(0.99) versus 0.39(0.84); p=0.015] compared with SCB 
patients. Pre-index health care utilization, including inpatient [0.44(0.85) versus 
0.29(0.68); p=0.006], ER [0.91(2.11) versus 0.60(1.13); p=0.015], physician office 
[10.06(9.86) versus 8.42(9.34); p=0.022] and outpatient visits [5.78(7.95) versus 
4.09(5.78); p=0.001], was higher in nSCB patients compared to SCB patients. 
CONCLUSIONS: Prior to the addition of lacosamide, nSCB patients had greater 
comorbidities, epilepsy-attributable events, and overall health care utilization 
compared to patients using SCB. These findings suggest that nSCB patients had a 
more severe clinical profile compared to SCB patients prior to adding 
lacosamide.  
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OBJECTIVES: During 2007-2011, Multiple Sclerosis (MS) was the only category 
that experienced triple digit growth in sales, leading to a doubling of their sales 
from $3.4 billion in 2007, to $7 billion in 2011. This has led to change in payer 
coverage and utilization of branded MS products. This study was undertaken to 
understand current trends in sales, access, and utilization management for MS 
products in the United States. METHODS: Sales data for MS branded products 
was analyzed using IMS Health 2007-2011 data. Access and utilization 
management trends were analyzed using preferred drug lists and coverage 
policies of top U.S. health plans. To understand new trends in coverage of MS 
products, primary discussions were conducted with pharmacy and medical 
directors to understand new trends in coverage of MS products. RESULTS: More 
than half (approximately 59%) of the branded MS products were covered by 
health plans as non-preferred products or at Tier 3/4. A significant majority (84%) 
of these products were covered with prior authorization or pre-certification 
criteria. Quantity limits were used by 34% of the plans. Use of step therapy or 
progression prescription is not currently common and was found in only 5% of 
the plans. In this sample (n=37), only one plan (<5%) had formulary exclusion for 
an MS product. Payer designated specialty pharmacies are increasingly being 
used by various health plans. Compared to 2007, payer coverage of MS products 
shows significant increase in use of PA (40% in 2007, vs. 84% in 2012). Payers 
express high concern for the rapidly growing MS category and report use of more 
utilization management approaches to control spending. CONCLUSIONS: MS 
products are facing more aggressive utilization management. Patient access for 
new MS therapies could be limited due to non-preferred status, high co-pay, or 
strict PA criteria.  
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OBJECTIVES: To examine the gene expression alterations in rat’s brain, treated 
by non-ionizing electromagnetic radiation from 900MHz-GSM mobile phone is 
main aim of this study. METHODS: We investigated whether an exposure of 
GSM-900 MHz irradiation from the mobile phone (3hours/day up to 28 days) 
could lead to the modulation of gene expression pattern in the rat brain. All rats 
were habitualised for one week prior to start the experiment in well designed 
circular mobile phone exposure (CCPE) cage. CCPE cage was specially designed 
for EMR exposure by mobile phone on the rats in the natural environment and it 
placed inside the exposure room where other electric appliances were not 
installed. In the cage, mobile phone was placed in the center and rats were 
